Press release
Biosimilar Monoclonal Antibodies Global Market Size, Share Analysis And Trends By 2033
Biosimilar Monoclonal Antibodies Global Market Size
According to The Business Research Company's, The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2023 to $9.25 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, growing acceptance of biosimilars by clinicians and patients.
The biosimilar monoclonal antibodies market size is expected to see rapidly grown in the next few years. It will grow to $12.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report
Market Drivers and Trends:
The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune diseases, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it is projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the prevalence of chronic diseases is expected to drive the growth of the biosimilar monoclonal antibodies market.
For instance, in July 2021, Abzena, a US-based partner research organization for biologics and bioconjugates, partnered with BioXpress Therapeutics to support biosimilar development for third-party customers. The collaboration aims to provide biosimilar medication manufacturers with an integrated approach to biosimilars that includes design advice, cell line and process development, and clinical and commercial GMP manufacturing. This collaboration enables the biosimilars sector to shorten drug development times. The strengths of BioXpress Therapeutics and Abzena are complementary, and this collaboration provides a flexible and innovative strategy from small-scale biosimilar development to large-scale manufacturing.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
Major Key Players of the Market:
Pfizer Inc.; Novartis AG; AbbVie Inc.; Coherus BioSciences; Biocon Limited; Amgen Inc.; Boehringer Ingelheim International GmbH; Celltrion Inc.; BioXpress Therapeutics SA; Intas Pharmaceuticals Limited; Genor BioPharma Co. Ltd.; BIOCAD; Dr. Reddy's Laboratories Ltd.; 3SBio Inc.; Reliance Life Sciences; Hisun Pharmaceuticals; Celgen Biopharmaceuticals; Torrent Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Shanghai Henlius Biotech Inc.; Teva Pharmaceutical Industries Ltd.; Alvotech; Xentria Inc.; Lazuline Biotech Private Limited; Epygen Biotech Pvt Ltd.; Mabpharm Limitied; Qilu Pharmaceutical Co. Ltd.; Chiatai Tianqing Pharmaceutical Group Co. Ltd.; YL Biologics Ltd.; Aprogen Biologics; UNDBIO Co Ltd.; Samsung Bioepis Co. Ltd.; ISU Abxis Corp.; Bio-Rad Laboratories Inc.
Biosimilar Monoclonal Antibodies Market 2024 Key Insights:
• The biosimilar monoclonal antibodies market size will grow to $12.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%.
• Rising Prevalence Of Chronic Diseases Fuels Growth In The Biosimilar Monoclonal Antibodies Market
• Abzena And Bioxpress Therapeutics Forge Strategic Partnership To Accelerate Biosimilar Development
• North America was the largest region in the biosimilar monoclonal antibodies market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=3412&type=smp
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Global Market Size, Share Analysis And Trends By 2033 here
News-ID: 3754498 • Views: …
More Releases from The Business research company
Packaging Inks and Coatings Industry Expected to Reach $6.47 Billion by 2029 at …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Packaging Inks and Coatings Market Value Projection: How Much Will the Market Size by 2025?
In recent times, there has been a consistent upward trend in the market size for packaging inks and coatings. The market, currently valued at $4.98 billion in 2024, is projected to rise to $5.21 billion in…
Inorganic Pigments Market Expansion Outlook: $39.38 Billion in 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Inorganic Pigments Market from 2024 to 2025?
The market size of inorganic pigments has experienced substantial growth in the past few years. It is projected to increase from a value of $29.19 billion in 2024 to $30.84 billion in 2025, registering a compound annual growth…
Latex Ink Market is Anticipated to Expand upto $24.28 Billion in 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Forecasted Market Growth Rate of the Latex Ink Industry?
The scale of the latex ink industry has been witnessing a consistent expansion in the past few years. Its market size is expected to escalate from $19.54 billion in 2024 to $20.36 billion in 2025 at a compound annual…
Future of Hydrofluoric Acid Market: Size, Share & Forecasts to 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Hydrofluoric Acid Market by 2025?
The scale of the hydrofluoric acid market has been expanding consistently in the past few years. It is expected to rise from $1.49 billion in 2024 to $1.55 billion in 2025, demonstrating a compound annual growth rate…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
